{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+%28GBM%29&page=3",
    "query": {
      "condition": "Glioblastoma (GBM)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1347,
    "total_pages": 135,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+%28GBM%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+%28GBM%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T20:08:58.992Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07733674",
      "title": "Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme (GBM)",
        "Pancreatic Ductal Adenocarcinoma (PDAC)"
      ],
      "interventions": [
        {
          "name": "203Pb-RMX-VHPIB injection",
          "type": "DRUG"
        },
        {
          "name": "SPECT/CT Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Radiomedix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-08-15",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07733674"
    },
    {
      "nct_id": "NCT05131815",
      "title": "The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Cancer Metastatic",
        "Neoplasms",
        "Breast Cancer",
        "Lung Cancer",
        "Thyroid Cancer",
        "Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Hodgkin Lymphoma",
        "Leukemia",
        "Sarcoma",
        "Skin Cancer",
        "Bone Cancer",
        "Gynecologic Cancer",
        "Pancreas Cancer",
        "Multiple Myeloma",
        "Colorectal Cancer",
        "Gastrointestinal Cancer",
        "Prostate Cancer",
        "Glioblastoma",
        "Brain Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Virtual group based physical activity (BurnAlong) and Social Media Discussion Board",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-07-25",
      "completion_date": "2023-06-15",
      "has_results": false,
      "last_update_posted_date": "2025-02-26",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05131815"
    },
    {
      "nct_id": "NCT00045708",
      "title": "A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "Anticonvulsant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2002-10",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-10-18",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045708"
    },
    {
      "nct_id": "NCT03630289",
      "title": "Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma Multiforme",
        "GBM",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-07-27",
      "completion_date": "2024-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630289"
    },
    {
      "nct_id": "NCT03347617",
      "title": "Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-12-20",
      "completion_date": "2025-06-23",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03347617"
    },
    {
      "nct_id": "NCT01547546",
      "title": "A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma, Glioma"
      ],
      "interventions": [
        {
          "name": "GDC-0084",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-04",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01547546"
    },
    {
      "nct_id": "NCT03452579",
      "title": "Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Standard Dose Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Peereboom",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2018-05-21",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452579"
    },
    {
      "nct_id": "NCT02067156",
      "title": "Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "G-202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GenSpera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2014-02",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02067156"
    },
    {
      "nct_id": "NCT01865162",
      "title": "Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "ketogenic diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mid-Atlantic Epilepsy and Sleep Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2013-01",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-09",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865162"
    },
    {
      "nct_id": "NCT03911388",
      "title": "HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms, Brain",
        "Glioblastoma Multiforme",
        "Glioblastoma of Cerebellum",
        "Neoplasms",
        "Astrocytoma",
        "Astrocytoma, Cerebellar",
        "Neuroectodermal Tumors",
        "Neuroectodermal Tumors, Primitive",
        "Cerebellar PNET, Childhood",
        "Cerebellar Neoplasms",
        "Cerebellar Neoplasms, Primary",
        "Cerebellar Neoplasm, Malignant",
        "Cerebellar Neoplasm Malignant Primary",
        "Neoplasm Metastases",
        "Neoplasm Malignant",
        "Neoplasms, Neuroepithelial",
        "Neoplasms, Germ Cell and Embryonal",
        "Neoplasms by Histologic Type",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms, Nerve Tissue",
        "Central Nervous System Neoplasms, Primary",
        "Central Nervous System Neoplasms, Malignant",
        "Nervous System Neoplasms",
        "Neoplasms by Site",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Medulloblastoma Recurrent",
        "HSV",
        "Virus",
        "Pediatric Brain Tumor",
        "Nervous System Cancer",
        "Primitive Neuroectodermal Tumor (PNET) of Cerebellum"
      ],
      "interventions": [
        {
          "name": "G207",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "36 Months to 22 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-12",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-10T20:08:58.992Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911388"
    }
  ]
}